Hedge Fund Stock Price Manipulation? Hedge Funds Weigh In On 2seventy bio
A number of institutional investors have recently bought and sold shares of TSVT. Goldman Sachs Group Inc. increased its position in 2seventy bio by 512.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,508,800 shares of the company’s stock worth $19,253,000 after buying an additional 3,772,556 shares during the last quarter.
The Goldman Sachs Group lowered shares of 2seventy bio (NASDAQ:TSVT – Free Report) from a neutral rating to a sell rating in a research note issued to investors on Thursday morning, Marketbeat Ratings reports. They currently have $2.00 target price on the stock, down from their prior target price of $5.00.
Something just doesn't add up here, does it? What do you think?
Several other analysts also recently issued reports on the company. Canaccord Genuity Group raised 2seventy bio to a strong-buy rating in a research note on Thursday, May 9th. Canaccord Genuity Group dropped their price target on 2seventy bio from $12.00 to $11.00 and set a buy rating on the stock in a research note on Thursday, May 9th. Citigroup lifted their price target on 2seventy bio from $9.00 to $12.00 and gave the company a buy rating in a research note on Monday, April 8th. Finally, Wedbush reissued a neutral rating and issued a $5.00 price target on shares of 2seventy bio in a research note on Monday, March 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $12.43.
https://www.americanbankingnews.com/2024/06/07/2seventy-bio-nasdaqtsvt-downgraded-to-sell-at-the-goldman-sachs-group.html
It's just an idea. But I bought a few of these good shares yesterday.
What's not to like about a company with a product that helps keep people from dying prematurely from skin cancer? Sounds to me that they have a product that most of the health care industry would like to own!
Maybe Bristol Myers Squibb will soon buy them out? Or perhaps some other health care company might be interested in taking on a part of the action?
TSVT already knows that they have found their golden goose. Now they are completely focused on that one product alone! But perhaps a bigger company could bring Abecma to market a lot faster if they completely controlled most of the picture!
Most stock analysts believe that 2seventy bio should be worth a lot more money than it is today!
I suspect that Goldman Sachs really believes the same. But like most of us, we would all prefer to buy our shares, so much cheaper! Has this hedge fund recently being doing most of the buying as these shares have been falling?
Haven't they recently encouraged others to sell as cheaply as possible?
It may be advantageous to create fear when that timing, suits them best!
Would they prefer to keep their shares and buy while others do the most of the selling?
Shorters do have some impact! Did they start the downward trend in the share price with this kind of action?
Are they now buying back their shorted shares while the retail crowd panics and sells?
Are you going to buy on Monday or continue to sell it down? Goldman might prefer that you sell! But when Goldman or other hedge fund players, finally figure out that it's time to scoop up all of the cheapest remaining asks, these shares should again, move up again, pretty damn fast!
And anyone else, continuing to short these shares will also help move the price up too! They will all have to buy back in!
So at what price point will opportunity knock the most?
How long are the hedge funds willing to wait?
Should we retailers move in before they drive the share price higher?
That would suit me, just fine!
All the best! Java